Evidence map›Paper›PMID 40557728›Full record

Observational studyDiabetes/metabolism research and reviews2025

Association of Albuminuria Within the Normoalbuminuric Range With All-Cause Mortality in People With Type 2 Diabetes.

Monia Garofolo, Giuseppe Penno, Anna Solini, Emanuela Orsi, Martina Vitale, Veronica Resi, Enzo Bonora, Cecilia Fondelli, Roberto Trevisan, Monica Vedovato and 3 more

Registry-linked trialAbstract readObservational StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Diabetes/metabolism research and reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00715481 (Reduced Estimated Glomerular Filtration Rate), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00715481 completednot on this map

Reduced Estimated Glomerular Filtration Rate (eGFR)and Prediction of Cardiovascular Disease and Renal Outcome in Subjects With Type 2 Diabetes: Italian Multicenter Study

TypeobservationalSponsorDiabetic Nephropathy Study GroupRan2008 to 2015Enrolled15,628ConditionsCardiovascular Disease
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Monia GarofoloDepartment of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.ORCID https://orcid.org/0000-0002-2518-3187
Giuseppe PennoDepartment of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.ORCID https://orcid.org/0000-0002-2834-4847
Anna SoliniDepartment of Surgical, Medical, Molecular and Critical Area Pathology, University of Pisa, Pisa, Italy.ORCID https://orcid.org/0000-0002-7855-8253
Emanuela OrsiDiabetes Unit, Fondazione IRCCS "Cà Granda - Ospedale Maggiore Policlinico", Milan, Italy.ORCID https://orcid.org/0000-0002-1255-8437
Martina VitaleDepartment of Clinical and Molecular Medicine, "La Sapienza" University, Rome, Italy.ORCID https://orcid.org/0000-0003-4856-7279
Veronica ResiDiabetes Unit, Fondazione IRCCS "Cà Granda - Ospedale Maggiore Policlinico", Milan, Italy.
Enzo BonoraDivision of Endocrinology, Diabetes and Metabolism, University and Hospital Trust of Verona, Verona, Italy.ORCID https://orcid.org/0000-0003-1074-5164
Cecilia FondelliDiabetes Unit, University of Siena, Siena, Italy.
Roberto TrevisanEndocrinology and Diabetes Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy.ORCID https://orcid.org/0000-0003-0420-4468
Monica VedovatoDepartment of Clinical and Experimental Medicine, University of Padua, Padua, Italy.
Antonio NicolucciCentre for Outcomes Research and Clinical Epidemiology (CORESEARCH), Pescara, Italy.ORCID https://orcid.org/0000-0002-5939-6850
Giuseppe PuglieseDepartment of Clinical and Molecular Medicine, "La Sapienza" University, Rome, Italy.ORCID https://orcid.org/0000-0003-1574-0397
Renal Insufficiency And Cariovascular Events (RIACE) Study Group

Funding

Boehringer IngelheimChiesi FarmaceuticiEli Lilly and CompanyFondazione Diabete Endocrinologia MetabolismoFondazione Diabete RicercaSigma-Tau PharmaceuticalsTakeda Pharmaceutical Company
6 · The paper itself

Abstract

aimsTo investigate the independent association of albuminuria within the normoalbuminuric range with all-cause mortality in normoalbuminuric people with type 2 diabetes with and without chronic kidney disease (CKD). MATERIALS AND

methodsThis observational, prospective, multicentre, cohort study enroled 15,773 individuals with type 2 diabetes in 2006-2008. At baseline, albumin excretion rate (AER) and estimated glomerular filtration rate (eGFR) were assessed together with cardiometabolic risk profile, treatments, complications, and comorbidities. All-cause mortality was verified on 31 October 2015.

resultsOf the 15,656 participants (99.3%) with valid information on vital status, 11,460 (71.2%) were normoalbuminuric, 9984 (87.1%) without and 1476 (12.9%) with CKD. Normoalbuminuric individuals were stratified into three (< 5, 5-15, and > 15 mg·day

conclusionsFor the same level of kidney function, higher AER within the normoalbuminuric range was independently associated with all-cause mortality, thus supporting to the use of albuminuria-lowering drugs in people with type 2 diabetes and mildly elevated albuminuria.

trial registrationClinicalTrials.gov, NCT00715481, retrospectively registered 15 July, 2008.

Indexed as

AlbuminuriaBiomarkersDiabetes Mellitus, Type 2Diabetic NephropathiesRenal Insufficiency, ChronicAgedCause of DeathFemaleFollow-Up StudiesGlomerular Filtration RateHumansMaleMiddle AgedPrognosisProspective StudiesRisk FactorsBiomarkersalbuminuriaall‐cause mortalitychronic kidney diseaseestimated glomerular filtration ratetype 2 diabetes

Identifiers

PMID40557728
PMCPMC12188507

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.